International Journal of Radiation Oncology * Biology * Physics
Volume 62, Issue 2 , Pages 606-613, 1 June 2005

Initial clinical results of an in vivo dosimeter during external beam radiation therapy

  • Charles W. Scarantino, M.D., Ph.D.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC, USA
    • Radiation Oncology, Rex Cancer Center, Raleigh, NC, USA
    • Corresponding Author InformationReprint requests to: Charles W. Scarantino, M.D., Ph.D., Sicel Technologies Inc., 3800 Gateway Centre Boulevard, Suite 308, Morrisville, NC 27560. Tel: (919) 465-2236 ext. 235; Fax: (919) 465-0153
  • ,
  • Christopher J. Rini, M.S.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC, USA
  • ,
  • Migdalia Aquino, B.S.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC, USA
  • ,
  • Tammy B. Carrea, B.S.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC, USA
  • ,
  • Robert D. Ornitz, M.D.

      Affiliations

    • Radiation Oncology, Rex Cancer Center, Raleigh, NC, USA
  • ,
  • Mitchell S. Anscher, M.D.

      Affiliations

    • Radiation Oncology, Duke University Medical Center, Durham, NC
  • ,
  • Robert D. Black, Ph.D.

      Affiliations

    • Sicel Technologies Inc., Morrisville, NC, USA

Received 29 April 2004; received in revised form 16 September 2004; accepted 22 September 2004. published online 01 February 2005.

Purpose: An implantable radiation dosimeter has been developed to monitor dose delivered at depth in patients undergoing external beam therapy. A clinical pilot study was conducted to test the safety, efficacy, and utility of the device.

Methods and Materials: Ten patients, all with unresectable malignant disease, were enrolled to assess implantation risk and movement of the device in the body and to compare the in vivo measured dose to the value predicted by the treatment planning system software.

Results: Migration of the sensor away from the point of original placement was noted in only 1 patient (due to unconsolidated host tissue) and no adverse events were recorded during the implantation procedure or thereafter. Daily dose measurements were recorded successfully for all sensors in all patients. Variance between measured and predicted dose values was reported as a frequency of error at the ≥5% and ≥8% levels. The error frequency at the ≥8% level was as high as 47%, 29%, and 21% for lung, prostate, and rectal tumors, respectively.

Conclusions: The implantable dosimeter was found to be safe and effective in measuring dose at depth. There are many factors that can influence delivered dose, and the implantable dosimeter measures the net effect of these factors. The daily sensor readings provide a new tool for rigorous treatment quality assurance.

Keywords:  Implantable dosimeter , Radiation therapy , Dose quality assurance

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported in part by National Cancer Institute R21 CA97859.

PII: S0360-3016(04)02693-8

doi:10.1016/j.ijrobp.2004.09.041

International Journal of Radiation Oncology * Biology * Physics
Volume 62, Issue 2 , Pages 606-613, 1 June 2005